Reuters logo
BRIEF-Aequus Pharma received positive feedback from FDA to pursue AQS1301
August 24, 2017 / 1:33 PM / 2 months ago

BRIEF-Aequus Pharma received positive feedback from FDA to pursue AQS1301

Aug 24 (Reuters) - Aequus Pharmaceuticals Inc

* Aequus Pharmaceuticals Inc - received positive feedback from FDA to pursue abbreviated 505(b)(2) clinical pathway for co’s AQS1301

* Aequus Pharmaceuticals- upon review of pre-IND submission, FDA agreed AQS1301 is suitable candidate for 505(b)(2) regulatory pathway for approval in U.S. Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below